{"altmetric_id":19493101,"counts":{"readers":{"mendeley":183,"citeulike":2,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["P McLaughlin","A J Grillo-L\u00f3pez","B K Link","R Levy","M S Czuczman","M E Williams","M R Heyman","I Bence-Bruckler","C A White","F Cabanillas","V Jain","A D Ho","J Lister","K Wey","D Shen","B K Dallaire"],"doi":"10.1200\/jco.1998.16.8.2825","first_seen_on":"2017-04-23T12:48:22+00:00","issns":["0732-183X","1527-7755"],"journal":"Journal of Clinical Oncology","last_mentioned_on":1412080145,"links":["http:\/\/dx.doi.org\/10.1200\/JCO.1998.16.8.2825"],"pubdate":"1998-08-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/rituximab-chimeric-anticd20-monoclonal-antibody-therapy-relapsed-indolent-lymphoma-half-patients-res"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7590305,"mean":6.5422694374256,"rank":1838131,"this_scored_higher_than_pct":62,"this_scored_higher_than":4739698,"rank_type":"exact","sample_size":7590305,"percentile":62},"similar_age_3m":{"total_number_of_other_articles":92816,"mean":11.928107288693,"rank":28636,"this_scored_higher_than_pct":68,"this_scored_higher_than":63309,"rank_type":"exact","sample_size":92816,"percentile":68},"this_journal":{"total_number_of_other_articles":7936,"mean":13.162062759924,"rank":3835,"this_scored_higher_than_pct":37,"this_scored_higher_than":2962,"rank_type":"exact","sample_size":7936,"percentile":37},"similar_age_this_journal_3m":{"total_number_of_other_articles":105,"mean":30.591384615385,"rank":75,"this_scored_higher_than_pct":27,"this_scored_higher_than":29,"rank_type":"exact","sample_size":105,"percentile":27}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":12,"Librarian":3,"Student  > Doctoral Student":12,"Researcher":20,"Student  > Ph. D. Student":33,"Student  > Postgraduate":13,"Other":20,"Student  > Master":28,"Student  > Bachelor":31,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":7},"by_discipline":{"Medicine and Dentistry":68,"Social Sciences":2,"Physics and Astronomy":2,"Unspecified":5,"Pharmacology, Toxicology and Pharmaceutical Science":5,"Chemical Engineering":1,"Arts and Humanities":1,"Engineering":2,"Chemistry":5,"Immunology and Microbiology":9,"Agricultural and Biological Sciences":64,"Biochemistry, Genetics and Molecular Biology":18,"Veterinary Science and Veterinary Medicine":1}}},"geo":{"mendeley":{"CO":1,"EC":1,"CZ":1,"AT":1,"US":2,"GB":3,"MX":1,"IL":1,"IQ":1,"EE":1,"ES":1}}},"posts":{"policy":[{"title":"Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia: Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/ta343\/documents\/leukaemia-chronic-lymphocytic-obinutuzumab-with-chlorambucil-1st-line-id650-evaluation-report2","license":"public","citation_ids":[6235475,3841381,19492989,1395611,19492805,19492804,771834,19492811,1088591,19492993,2037163,4101823,904178,19492820,19492994,1213168,1713989,3260672,2536307,231404,5983279,3123828,19492996,19492997,19492999,19493002,21718986,19492812,4351077,537513,7407967,19493006,19493008,21718987,2029938,1145378,5907633,13937057,19492818,4048127,10366163,19493016,1587287,1587282,19493019,5737691,19493024,19493027,19493029,19493031,5904841,3260675,19493040,1829099,19493047,19493049,1039105,19493053,19493057,536288,19493058,19493059,19493060,229170,19493063,19493065,21718989,236543,19493067,21718991,19493069,19493072,652959,19493076,19493081,442919,231402,210413,5727653,5758902,5759619,19493092,3420891,15727255,19493098,234877,19493101,6079279],"posted_on":"2014-09-30T12:29:05+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta343\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-6ccefb248ec20a377c857d443c729192c5d45119106aa8652586175e99f907b0.jpg"}}]}}